Status:
COMPLETED
Creatine to Augment Bioenergetics in Alzheimer's
Lead Sponsor:
University of Kansas Medical Center
Collaborating Sponsors:
Alzheimer's Association
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
60-90 years
Phase:
NA
Brief Summary
By doing this study, researchers hope to see if creatine monohydrate is a helpful treatment for people with Alzheimer's disease.
Detailed Description
Alzheimer's disease is a progressive brain disorder that causes memory and thinking problems. Current medications may temporarily help with symptoms but cannot stop the disease from getting worse. As ...
Eligibility Criteria
Inclusion
- Diagnosed cognitive impairment due to Alzheimer's disease
- Agreed cooperation from a study partner
- Speaks English as primary language
- Age 60 to 90
- Stable medication for ≥30 days
- BMI ≥ 20.0kg/m2
Exclusion
- Insulin-requiring diabetes, cancer requiring chemotherapy or radiation within the past 5 years, or recent cardiac event (i.e., heart attack, etc.)
- Other neurodegenerative disease
- Ongoing renal disorder or abnormal renal or liver function
- Unable to undergo MRI
- Clinical trial or investigational drug or therapy participation within 30 days of the screening visit
- Non-English speakers
- Inability to perform strength testing
- Weight \> 350 lbs.
Key Trial Info
Start Date :
December 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05383833
Start Date
December 12 2022
End Date
May 14 2024
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160